[CAS NO. 385425-03-6] IBS008738

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [385425-03-6]

Catalog

AS984795

Brand

Arctom Scientific

CAS

385425-03-6

DESCRIPTION [385425-03-6]

Overview

MDL	-
Molecular Weight	374.44
Molecular Formula	C22H22N4O2
SMILES	O=C(C1=C(/N=C/N2CCOCC2)N=CN1C3=CC=C(C)C=C3)C4=CC=CC=C4

For research use only. We do not sell to patients.

Summary

IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model ^[1] ^[2] .

IC50 & Target

TAZ ^[1]

In Vitro

IBS008738 (0, 24, 48, 72 h) enhances TAZ expression, with a peak at 24 h ^[1] .
IBS008738 (10 μM; 0, 24, 72 h) enhances mRNAs of myogenic markers but not of myofusion markers ^[1] .
IBS008738 (10 μM; 24h) enhances mRNAs of IL-10 in C2C12 cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis ^[1]

Cell Line:	C2C12 cells
Concentration:
Incubation Time:	Treated for 0, 24, 48, 72 h under differentiation conditions after 24 h under growth conditions.
Result:	Enhanced TAZ expression, with a peak at 24 h.

RT-PCR ^[1]

Cell Line:	C2C12 cells
Concentration:	10 μM
Incubation Time:	0, 24, 72 h under differentiation
Result:	Enhanced mRNAs of myogenic markers but not of myofusion markers.

In Vivo

IBS008738 (3 nmol) facilitates muscle repair in Cardiotoxin-injected muscles ^[1] .
IBS008738 (30 μM, 100 μL) prevents Dexamethasone-induced muscle atrophy ^[1] .
IBS008738 (100-μL volume of 30 μM; intramuscular injection; immediately and on day 2 after TBI) diminishes the expression of TNF α and IL-6 but increases that of IL-10 mRNAs in muscles of traumatic brain injury (TBI) ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female BALB/cByJ mice ^[1]
Dosage:	3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS)
Administration:	Injected into the tibialis anterior (TA) muscle of mice under anesthesia.
Result:	Facilitated muscle repair in Cardiotoxin-injected muscles.

Animal Model:	Six-week-old female BALB/cByJ mice ^[1]
Dosage:	30 μM (100 μL)
Administration:	Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13.
Result:	Prevented Dexamethasone-induced muscle atrophy.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 133.53 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6707 mL	13.3533 mL	26.7065 mL
5 mM	0.5341 mL	2.6707 mL	5.3413 mL
10 mM	0.2671 mL	1.3353 mL	2.6707 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1.25 mg/mL (3.34 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1.25 mg/mL (3.34 mM); Clear solution

* All of the co-solvents are available by MCE.